HLB Life Science Co., Ltd. (KOSDAQ:067630)

South Korea flag South Korea · Delayed Price · Currency is KRW
4,040.00
-30.00 (-0.74%)
Aug 14, 2025, 2:40 PM KST
-63.17%
Market Cap 491.65B
Revenue (ttm) 105.82B
Net Income (ttm) -196.10B
Shares Out 121.85M
EPS (ttm) -1,674.61
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 359,886
Average Volume 595,586
Open 4,070.00
Previous Close 4,070.00
Day's Range 3,970.00 - 4,100.00
52-Week Range 3,980.00 - 12,520.00
Beta -0.30
RSI 28.08
Earnings Date Aug 14, 2025

About HLB Life Science

HLB Life Science Co., Ltd. develops and manufactures in vitro diagnostic medical devices and quasi-drugs in South Korea and internationally. It also develops Rivoceranib, a small-molecule tyrosine kinase inhibitor for the treatment of various cancers, including gastric cancer, colon cancer, hepatocellular carcinoma, non-small cell lung cancer, breast cancer, mesothelioma, renal cell carcinoma, and neuroendocrine tumors; and Pyrotinib, an anticancer drug that inhibits the proliferation, division, and survival of cancer cells. In addition, the co... [Read more]

Sector Utilities
Founded 1998
Employees 153
Stock Exchange KOSDAQ
Ticker Symbol 067630
Full Company Profile

Financial Performance

Financial Statements

News

There is no news available yet.